

Copper-Mediated Amidation of
Heterocyclic and Aromatic C–H Bonds


Qiu Wang and Stuart L. Schreiber*

Howard Hughes Medical Institute, Broad Institute, Cambridge, Massachusetts 02142,
and Department of Chemistry and Chemical Biology, Harvard University,
Cambridge, Massachusetts 02138

stuart_schreiber@harvard.edu

Received September 9, 2009

ABSTRACT




A copper-mediated aerobic coupling reaction enables direct amidation of heterocycles or aromatics having weakly acidic C–H bonds with a variety of nitrogen nucleophiles. These reactions provide efficient access to many biologically important skeletons, including ones with the potential to serve as inhibitors of HMTs.

The methylation marks on chromatin established by histone methyltransferases (HMTs) are key elements of heritable cell states and can lead to disease when dysregulated.^{1,2} Thus, it was of interest that a compound containing a 2-amidobenzimidazole skeleton was reported to inhibit several HMTs.³ Methods to synthesize this skeleton require multiple-step

sequences that do not easily lend themselves to syntheses of many structural analogues.⁴ To overcome this obstacle, we describe here the direct C–H functionalization of benzimidazoles with nitrogen-containing reagents via a copper(II)-mediated oxidative coupling that affords 2-amidobenzimidazoles.

We anticipated that the aerobic cross-coupling of heterocycles (I) with nucleophiles would lead to the 2-amido-substituted heterocycles (III) through the organocopper intermediate (II) in analogy to the Chan–Lam oxidative coupling of arylboronic acids and nucleophiles (Scheme 1).^{5–7}

Scheme 1. Copper-Mediated C–H Functionalization of Heterocyclic C–H Bonds



We first examined the reaction of *N*-methylbenzimidazole (1) with pyrrolidinone (2a) in the presence of catalytic copper salts under 1 atm of O₂. In the initial screening of Cu sources, Brønsted bases, and solvents, optimal results were observed with 0.2 equiv of Cu(OAc)₂ and 2 equiv

(1) (a) Schreiber, S. L.; Bernstein, B. E. *Cell* **2002**, *111*, 771–778. (b) Bernstein, B. E.; Mikkelsen, T. S.; Xie, X.; Kamal, M.; Huebert, D. J.; Cuff, J.; Fry, B.; Meissner, A.; Wernig, M.; Plath, K.; Jaenisch, R.; Wagschal, A.; Feil, R.; Schreiber, S. L.; Lander, E. S. *Cell* **2006**, *125*, 315–326. (c) Kouzarides, T. *Cell* **2007**, *128*, 693–705.









(2) (a) Cole, P. A. *Nat. Chem. Biol.* **2008**, *4*, 590–597. (b) Marks, P. A.; Breslow, R. *Nat. Biotechnol.* **2007**, *25*, 84–90. (c) Copeland, R. A.; Solomon, M. E.; Richon, V. M. *Nat. Rev. Drug Discov.* **2009**, *8*, 724–732.

(3) (a) Kubicek, S.; O'Sullivan, R. J.; August, E. M.; Hickey, E. R.; Zhan, Q.; Teodoro, M. L.; Rea, S.; Mechtler, K.; Kowalski, J. A.; Homon, C. A.; Kelly, T. A.; Jenuwein, T. *Mol. Cell* **2007**, *25*, 473–481. Other recently reports on biological activities of 2-aminobenzimidazole cores: (b) Winters, M. P.; Robinson, D. J.; Khine, H. H.; Pullen, S. S.; Woska, J. R.; Raymond, E. L.; Sellati, R.; Cywin, C. L.; Snow, R. J.; Kashem, M. A.; Wolak, J. P.; King, J.; Kaplita, P. V.; Liu, L. H.; Farrell, T. M.; DesJarlais, R.; Roth, G. P.; Takahashi, H.; Moriarty, K. J. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5541–5544. (c) Powers, J. P.; Li, S. Y.; Jaen, J. C.; Liu, J. Q.; Walker, N. P. C.; Wang, Z. L.; Wesche, H. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2842–2845. (d) Kim, R. M.; Chang, J.; Lins, A. R.; Brady, E.; Candelore, M. R.; Dallas-Yang, Q.; Ding, V.; Dragovic, J.; Iliff, S.; Jiang, G. Q.; Mock, S.; Qureshi, S.; Saperstein, R.; Szalkowski, D.; Tamvakopoulos, C.; Tota, L.; Wright, M.; Yang, X. D.; Tata, J. R.; Chapman, K.; Zhang, B. B.; Parmee, E. R. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3701–3705.

(4) (a) Carpenter, R. D.; DeBerdt, P. B.; Lam, K. S.; Kurth, M. J. *J. Comb. Chem.* **2006**, *8*, 907–914. (b) Perkins, J. J.; Zartman, A. E.; Meissner, R. S. *Tetrahedron Lett.* **1999**, *40*, 1103–1106. (c) Seth, P. P.; Robinson, D. E.; Jefferson, E. A.; Swayze, E. E. *Tetrahedron Lett.* **2002**, *43*, 7303–7306.

of Na₂CO₃ with pyridine as additive in toluene.⁸ The dimeric product **4** was observed in many conditions, but its formation was suppressed and the yield of **3a** was increased by using 5 equiv of nucleophile (Table 1, entry

Table 1. Cu(II)-Mediated Oxidative Coupling of **1** with *N*-Nucleophiles^a

			
entry	<i>N</i> -nucleophile	product	yield of 3 (4) ^b
1			3a 82% (10%)
2	2b <i>n</i> = 2		3b 55% (35%)
3	2c <i>n</i> = 4		3c 55% (40%)
4			3d 45% (40%) ^c
5	2e <i>X</i> = NMe, <i>R</i> = H		3e 72%
6	2f <i>X</i> = O, <i>R</i> = Bn		3f 64%
7			3g 50% (38%) ^d
8			3h 85% (<5%) ^e
9	2i <i>R</i> ₁ = H, <i>R</i> ₂ = H		3i 91%
10	2j <i>R</i> ₁ = CF ₃ , <i>R</i> ₂ = H		3j 72%
11	2k <i>R</i> ₁ = OMe, <i>R</i> ₂ = H		3k 70%
12	2l <i>R</i> ₁ = H, <i>R</i> ₂ = CF ₃		3l 67%
13			3m 58%
14	2n <i>R</i> = CF ₃		3n 68%
15			3o 97%
16	2p <i>R</i> = 4-MeC ₆ H ₄		3p 86%

^a Reaction conditions for **2a–2g**. Condition A: **1** (0.3 mmol), **2** (1.5 mmol), pyridine (6.0 mmol), Cu(OAc)₂ (0.06 mmol), Na₂CO₃ (0.6 mmol), toluene (10 mL), O₂ (balloon), 120–140 °C, 12–30 h. For **2h–2p**. Condition B: **1** (0.3 mmol), **2** (1.5 mmol), pyridine (6.0 mmol), Cu(OAc)₂ (0.6 mmol), Na₂CO₃ (0.9 mmol), toluene (10 mL), O₂ (balloon), 120–140 °C, 12–30 h. ^b Yields correspond to isolated products. ^c Cu(OAc)₂ (0.3 mmol). ^d **2g** (0.6 mmol), pyridine (1.5 mmol). ^e Yield of product **3h** under condition A.

1). Among the Cu sources tested, Cu(OAc)₂ generally performed better than CuCl₂, CuBr₂, Cu(OTf)₂, and Cu(O₂CCF₃)₂.

We next varied the nucleophiles in this reaction (Table 1). Cyclic amide (entries 2 and 3), urea and carbamate (entries 4–6) nucleophiles, and *N*-methyl benzenesulfonamide (entry 7) provided the desired products effectively, while acyclic secondary amides were not effective under

similar reaction conditions. A wide range of primary amides was found to undergo the reaction (Table 1, entries 8–16). The reaction with benzamide **2h** using a catalytic amount of Cu(OAc)₂ formed product **3h**; however, the starting material **1** was not effectively consumed. This may be due to the binding of Cu(II) to the carbonyl oxygen and imino nitrogen in the product. This problem was circumvented by using 2 equiv of Cu(OAc)₂ (entry 8). Both electron-withdrawing and electron-donating functional groups are tolerated well on the aryl ring of the amides (entries 9–12). Simple alkyl primary amides are also substrates (entries 13 and 14), even ones with steric bulk on the amide. Reactions of **1** with sulfonamides resulted in excellent yields (entries 15 and 16), including one with a bromine substituent on the aryl group. Although reactions with amines under the same conditions provided the desired products, the formation of the dimeric product **4** was significant, most likely due to strong electron donation by the amine and the unfavorable deprotonation.

We also investigated the scope of this reaction with other heterocyclic and aromatic C–H bonds (Table 2). In the amidation reactions with pyrrolidinone **2a**, the heterocyclic C–H bonds of benzothiazole, caffeine, and oxazole all underwent oxidative coupling (entries 1–3). Similar reactions with primary amide **2i** were successful (entries 4 and 5), and intramolecular reactions delivered cyclic products with excellent yields (entries 6 and 7). The reaction condition was also effective for the direct amidation of C–H bonds in fluorinated aromatic rings, albeit in diminished yields (entries 8–10). These transformations offer successful examples of challenging intermolecular C–N bond formation using aromatic C–H and amide N–H groups. These amidation reactions (entries 8–10) indicate the potential of this method in the synthesis of fluorobenzene derivatives.

Although mechanisms of copper-catalyzed oxidative C–N couplings have been proposed,⁶ the details remain uncertain. A proposed mechanism for this amidation reaction is outlined in Scheme 2. In the presence of Cu(II) and base, we imagine that organocopper intermediate **1a** from the heterocycle (e.g., **1**) is formed. Ligand exchange with the deprotonated nucleophile would yield intermediate **1b**. C–N reductive elimination and aerobic reoxidation of the catalyst would complete the catalytic cycle.

















Since the formation of **1b** can compete with the formation of **1c**, dimer **4** will form when **1b** is disfavored by slow deprotonation (e.g., p*K*_a > 25 or amine) or steric hindrance (e.g., primary vs secondary amides). Reactions with pyridone (p*K*_a = 17) and phthalimide (p*K*_a = 8.3) only resulted in the

(5) (a) Chan, D. M. T.; Monaco, K. L.; Wang, R. P.; Winters, M. P. *Tetrahedron Lett.* **1998**, 39, 2933–2936. (b) Lam, P. Y. S.; Clark, C. G.; Saubern, S.; Adams, J.; Winters, M. P.; Chan, D. M. T.; Combs, A. *Tetrahedron Lett.* **1998**, 39, 2941–2944. (c) Evans, D. A.; Katz, J. L.; West, T. R. *Tetrahedron Lett.* **1998**, 39, 2937–2940.

(6) For a related reaction involving directed functionalization of C–H bond with *N*-nucleophiles, see: (a) Hamada, T.; Ye, X.; Stahl, S. S. *J. Am. Chem. Soc.* **2008**, 130, 833–835. (b) Balsamo, A.; Macchia, B.; Macchia, F.; Rossello, A.; Domiano, P. *Tetrahedron Lett.* **1985**, 26, 4141–4144. (c) King, A. E.; Brunold, T. C.; Stahl, S. S. *J. Am. Chem. Soc.* **2009**, 131, 5044–5045.


(7) For examples involving transition-metal-directed functionalization of C–H bonds with heteroatoms, see: (a) Chen, X.; Hao, X.-S.; Goodhue, C. E.; Yu, J.-Q. *J. Am. Chem. Soc.* **2006**, 128, 6790–6791. (b) Uemura, T.; Imoto, S.; Chatani, N. *Chem. Lett.* **2006**, 35, 842–843. Intramolecular: (c) Brasche, G.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2008**, 47, 1932–1934. (d) Thu, H.-Y.; Yu, W.-Y.; Che, C.-M. *J. Am. Chem. Soc.* **2006**, 128, 9048–9049. (e) Wasa, M.; Yu, J.-Q. *J. Am. Chem. Soc.* **2008**, 130, 14058–14059. (f) Inamoto, K.; Hasegawa, C.; Hiroya, K.; Doi, T. *Org. Lett.* **2008**, 10, 5147–5150. (g) Jordan-Hore, J. A.; Johansson, C. C. C.; Gulias, M.; Beck, E. M.; Gaunt, M. J. *J. Am. Chem. Soc.* **2008**, 130, 16184–16186. (h) Ueda, S.; Nagasawa, H. *Angew. Chem., Int. Ed.* **2008**, 47, 6411–6413. (i) Mei, T.-S.; Wang, X.; Yu, J.-Q. *J. Am. Chem. Soc.* **2009**, 131, 10806–10807.

Table 2. Cu(II)-Mediated Amidations of Aromatic C–H Bonds^a

entry	substrate and <i>N</i> -nucleophile	product	yield
1	 5 2a	 5a	45%
2	 6 2a	 6a	42%
3	 7 2a	 7a	84%
4	6 2i	 6i	63% ^b
5	 8 2i	 8i	76% ^b
6	 9	 11	86% ^c
7	 10 $n = 1$ $n = 2$	 12 $n = 1$ $n = 2$	86% ^c 90% ^c
8	 13 2a	 13a	22% ^d
9	 14 2a	 14a	33% ^e
10	14a 2a	 14aa	71% ^d

^a Standard reaction condition: heterocycle (1.0 equiv), nucleophile (5.0 equiv), Cu(OAc)₂ (0.2 equiv), Na₂CO₃ (2.0 equiv), pyridine (20.0 equiv), toluene, O₂ (balloon), 120–140 °C, 12–30 h. Yields correspond to isolated products.
^b Cu(OAc)₂ (2.0 equiv), Na₂CO₃ (3.0 equiv). ^c Cu(OAc)₂ (1.0 equiv), pyridine (5.0 equiv). ^d Cu(OAc)₂ (1.0 equiv), K₂CO₃ (2.0 equiv) instead of Na₂CO₃. ^e **14** (5.0 equiv), **2a** (1.0 equiv), pyridine (5.0 equiv), K₂CO₃ (2.0 equiv).

recovery of starting material, which suggests that the nucleophilicity of the substrates plays an important role in

Scheme 2. Proposed Mechanism for Copper-Mediated C–H Functionalization of Heterocyclic C–H Bonds

the reaction, presumably by facilitating the C–N reductive elimination step.

In conclusion, we have developed a copper-mediated method for aerobic coupling of 2-benzimidazoles and other heterocycles or aromatics having acidic C–H bonds with a variety of nitrogen nucleophiles. These reactions provide efficient access to many biologically important skeletons, including ones with the potential to serve as inhibitors of HMTs.⁹

Acknowledgment. We gratefully acknowledge the National Cancer Institute (NCI-PO1-CA078048) for support of this research. S.L.S. is a Howard Hughes Medical Institute Investigator.

Supporting Information Available: Experimental procedures, additional screening data, and characterization data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL902079G

(8) See Supporting Information.

(9) During the preparation of this paper, a related study of C–H amination of benzothiazoles, benzimidazoles, benzoxazoles, and thiazoles was reported: Monguchi, D.; Fujiwara, T.; Furukawa, H.; Mori, A. *Org. Lett.* **2009**, *11*, 1607–1610.